5065 Background: There is a perception that pts receiving high-dose chemotherapy with autologous stem cell support (HDCT) experience long-term detriments to overall QOL. To assess if changes in QOL differ between women receiving HDCT and CDCT, a prospective single-institution study was conducted to longitudinally assess QOL of ovca pts enrolled on a phase II trial of HDCT and newly diagnosed pts scheduled to begin CDCT. Methods: The FACT-O was used to assess QOL at 4 time points (T1, T2, T3, T4) in two groups of pts. CDCT consisted of 6 cycles of platinum/paclitaxel. HDCT consisted of mobilization regimen (MOB) of ifosfamide/etoposide, followed by high-dose topotecan, melphalan and cyclophosphamide (TMC). For CDCT pts, T1= pre-cycle #1 and T2 =cycle #6. For HDCT pts, T1=MOB and T2 = post-TMC (during engraftment). For all pts, T3 and T4 occurred at 3 and 6 months follow-up, respectively. The FACT-O consists of 4 domains [physical (PHYS), social (SOC), emotional (EMO), and functional well-being (FUNC)] and the ovca subscale (OV). The Mann-Whitney U test was used to compare changes in pts’ QOL scores. Results: To date, 39 HDCT and 19 CDCT pts have participated. All patients were alive at T4. At T1 CDCT pts had worse FUNC (p=.006) and OV (p=.009) scores than HDCT pts; however PHYS, SOC and EMO scores were similar between both groups. At T2, HDCT pts had worse PHYS (p=.003), FUNC (p=.04) and OV (p=.03)scores than CDCT pts. HDCT pts had significantly worse changes than CDCT pts from T1 to T2 for PHYS, FUNC and OV (p<.001). Both HDCT and CDCT pts had better PHYS, FUNC and OV scores at 3 months and 6 months follow-up compared to each group’s baseline scores (p=.02 to .006) At 3 months follow-up, HDCT pts reported higher PHYS (p=.04), FUNC and OV scores than CDCT pts. At 6 months follow-up, both groups reported identical levels of PHYS, FUNC and OV well-being. Conclusions: Compared to CDCT pts, HDCT pts reported lower PHYS and FUNC well-being during treatment, however, both groups of women returned to normal or better levels in all QOL domains compared to their pre-treatment levels. Our data suggest that pts receiving HDCT return to normal QOL and may exceed levels reported by CDCT pts. No significant financial relationships to disclose.